Comparing chemo‑immunotherapy options for metastatic NSCLC with PD‑L1 <50%

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort that follows adults with stage IV NSCLC and tumor PD‑L1 <50% treated in routine clinical practice. Two commonly used approaches—chemotherapy plus pembrolizumab, and chemotherapy combined with nivolumab plus ipilimumab—will be recorded based on treating physicians' choices without randomization. The main outcomes are progression‑free survival and overall survival measured from standard clinical and radiological follow‑up; health‑related quality of life will be collected with validated patient‑reported questionnaires. Exploratory analyses will examine associations between outcomes and patient factors such as biological age metrics and recent antibiotic exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years.
* Histologically or cytologically confirmed non-small cell lung cancer.
* Metastatic (stage IV) disease at the time of study entry.
* Tumor PD-L1 expression \<50%.
* Initiation of first-line systemic treatment with either chemotherapy plus pembrolizumab or nivolumab plus ipilimumab in combination with chemotherapy, according to routine clinical practice.
* Ability to provide informed consent.

Exclusion Criteria:

* Prior systemic therapy for metastatic non-small cell lung cancer.
* Participation in an interventional clinical trial that mandates treatment assignment.
* Presence of another active malignancy requiring systemic treatment.
* Inability to comply with routine clinical follow-up or data collection.

Where it's running

• Ankara Etlik City Hospital
  Ankara, Turkey (Türkiye) Recruiting
• Gazi University Faculty of Medicine, Department of Medical Oncology
  Ankara, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Orhun Akdogan, MD
• Email: orhun.akdogan@gazi.edu.tr
• Phone: +905375831594

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-Line Nivolumab plus Ipilimumab in unresectable hepatocellular carcinoma

  This study tests whether the combination of nivolumab and ipilimumab is safe and effective for adults with unresectable liver cancer in real-world care in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07679061

• 30-minute cycling immediately before nivolumab and ipilimumab for metastatic melanoma

  This trial will test whether a 30-minute cycling session immediately before nivolumab plus ipilimumab boosts immune activity and improves outcomes for people with metastatic melanoma.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07564570

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Y90 liver radiation plus immunotherapy and targeted drug for unresectable liver cancer

  This test will see if adding Y90 liver radiation to nivolumab, ipilimumab, and lenvatinib helps people with unresectable hepatocellular carcinoma live longer and have better tumor responses.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07482059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.